Johannes Ruebenthaler

31PUBLICATIONS
39CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer diagnosisRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|May 14, 2025
Comparison of the Hematotoxicity of PRRT with Lutathera® and Locally Manufactured 177Lu-HA-DOTATATE in Patients with Neuroendocrine Tumors and the Impact of Different Application Intervals.

Markus Hofmann, Sophie C Kunte, Marcus Unterrainer

|Oct 27, 2022
Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters.

Maria Ingenerf, Sophia Kiesl, Michael Winkelmann

|Sep 23, 2022
Radiomics for the Prediction of Overall Survival in Patients with Bladder Cancer Prior to Radical Cystectomy.

Piotr Woźnicki, Fabian Christopher Laqua, Katharina Messmer

|May 14, 2022
Diagnostic Workup for Patients with Solid Renal Masses: A Cost-Effectiveness Analysis.

Jasmin Runtemund, Johannes Rübenthaler, Niklas von Münchhausen

|Feb 15, 2022
Initial Evaluation of Therapy Response after Adjuvant Radioiodine Therapy in Patients with Early-Stage Papillary Thyroid Cancer-Does Time Matter?

Freba Grawe, Yuri Cramm, Matthias P Fabritius

|Jan 21, 2022
Sequential Organ Failure Assessment Outperforms Quantitative Chest CT Imaging Parameters for Mortality Prediction in COVID-19 ARDS.

Daniel Puhr-Westerheide, Jakob Reich, Bastian O Sabel

Pageof 6

Frequent Collaborators

13 joint publications

Matthias Frank Froelich

8 joint publications

Matthias Philipp Fabritius

5 joint publications

Dirk-André Clevert

5 joint publications

Andrei Todica